Are Cancer-Screening Blood Tests Ready for Prime Time?

Cancer blood tests that detect tiny amounts of DNA circulating in the bloodstream have advanced rapidly in recent years, moving from protein-based analyses to sophisticated algorithms that identify genetic changes suggestive of cancer. The vision of a single blood test capable of screening for dozens of cancer types at an early, treatable stage has long motivated researchers, and clinicians. However, the largest trial to date on such a test failed to meet its primary objective, raising questions about how close these tests are to widespread clinical use.

The trial, conducted by Grail, a biotechnology company, evaluated its Galleri test, which claims to detect more than 50 types of cancer by measuring DNA fragments in the blood. Despite the test’s ability to identify cancer signals in earlier studies, the results released by the company showed no significant reduction in advanced cancer diagnoses among those who received the Galleri test compared to those who did not. This outcome indicates that, while the test can detect cancer, it has not yet demonstrated a clear benefit in reducing late-stage diagnoses in a real-world screening setting.

Dr. Aadel Chaudhuri, a radiation oncologist at the Mayo Clinic in Rochester, Minnesota, who is researching multi-cancer blood tests, noted the scientific progress made over the past decade. “It’s amazing One can even do this,” he said. “If you had asked me 10 years ago, my answer would have been ‘It’s not feasible.’ If we’re thinking of DNA shed from a small tumor, it’s like being on the beltway in D.C. And you’re looking for one Volkswagen.” His remarks reflect both the technological achievement and the immense challenge of detecting vanishingly small amounts of tumor-derived DNA in the bloodstream.

Earlier research has shown promise for similar approaches. In one study, a blood test called Mercury correctly identified 13 cancers with an average accuracy of 87%, including 77% of stage 1 cancers. These results suggest that the underlying science is capable of detecting early-stage disease, which is critical because cancers caught at an early stage are more likely to be curable. The ultimate goal of multi-cancer early detection tests is to find malignancies soon enough to improve survival rates and reduce cancer-related deaths.

Despite these advances, no professional medical societies currently recommend multi-cancer early detection tests for routine use. Experts emphasize that the central question is not whether the tests can detect cancer, but whether they can find cancers early enough to reduce mortality. The failure of the Grail trial to show a significant impact on advanced cancer diagnoses underscores the gap between technical detection ability and proven clinical benefit in a screening context.

Researchers and oncologists remain cautiously optimistic about the future of cancer blood tests. While the recent trial results are disappointing, they do not invalidate the underlying approach. Instead, they highlight the need for further refinement in test sensitivity, specificity, and the ability to identify cancers at the earliest possible stage. Ongoing studies will need to determine whether adjustments to the technology or screening protocols can translate early detection into meaningful reductions in cancer deaths.